Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.85 |
| ▸ | KDR | P35968 | 3/20 | 0.85 |
| ▸ | RET | P07949 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 2/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | FBP1 | P09467 | 4/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515328 | 0.92 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL1257431 | 0.92 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL22338291 | 0.91 | EGFR (0.83) | EGFRKDRRETLCKRIPK2 | |
| Hydrochloric Acid SCHEMBL5475737 | 0.91 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL1387182 | 0.90 | EGFR (0.94) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL30891782 | 0.89 | EGFR (0.83) | EGFRKDRRETLCKRIPK2 | |
| Hydrochloric Acid SCHEMBL8807895 | 0.88 | EGFR (0.95) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL12963484 | 0.87 | FBP1 (0.91) | EGFRKDREPHB2SRCFBP1 | |
| SCHEMBL13604740 | 0.86 | EGFR (0.66) | EGFRKDRRETLCKFBP1 | |
| SCHEMBL5238437 | 0.86 | EGFR (0.77) | EGFRKDRRETLCKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070032513-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | EGFR 3/4885KDR 225/4885RET 51/4885 |
| US-20070032513-A1 | Quinazoline derivatives | ERBB2, EGFR, ABL1 | EGFR 2/4885KDR 124/4885RET 56/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | EGFR 3/4885KDR 180/4885RET 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.